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Acute respiratory distress syndrome (ARDS) is a medical emergency that threatens 
life. To this day, ARDS is very rarely reported by iodine contrast media, and there is 
no reported case of ARDS induced by gadolinium contrast media. Here, we present 
a case with ARDS after the use of gadobutrol (Gadovist) as a magnetic resonance 
imaging (MRI) contrast medium. A 26 years old female without any medical histo-
ry, including allergic diseases and without current use of drugs, visited the emergen-
cy room for abdominal pain. Her abdominopelvic computed tomography with io-
dine contrast media showed a right ovarian cyst and possible infective colitis. 
Eighty-three hours later, she underwent pelvis MRI after injection of 7.5 mL (0.1 
mL/kg body weight) of gadobutrol (Gadovist) to evaluate the ovarian cyst. She soon 
presented respiratory difficulty, edema of the lips, nausea, and vomiting, and we 
could hear wheezing upon auscultation. She was treated with dexamethasone, epi-
nephrine, and norepinephrine. Her chest X-ray showed bilateral central bat-wing 
consolidative appearance. Managed with mechanical ventilation, she was extubated 
3 days later and discharged without complications.
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INTRODUCTION
Gadolinium-based contrast media have been used since 25 years ago because of 
their safety and low rates of side effects. Gadobutrol is a second-generation extra-
cellular non-ionic macrocyclic gadolinium based contrast agents with high thermo-
stability. Its gadolinium ion concentration is twice as high as other gadolinium 
agents, effectively resulting in high-quality images with low amount.1
Adverse reactions due to radiologic contrast media are not rare, but those accom-
panied with acute respiratory distress syndrome (ARDS) by contrast media are ex-
tremely rare. To our best knowledge, only two cases of noncardiogenic pulmonary 
edema induced by ionic computed tomography (CT) contrast media, such as diatri-
zoate and iothalamatemeglumine, have so far been reported.2,3 Also, no case of 
ARDS induced by magnetic resonance imaging (MRI) gadolinium contrast media 
has been reported yet. Here, we present a young woman who developed ARDS af-
ter the use of gadobutrol.
Case Report http://dx.doi.org/10.3349/ymj.2015.56.4.1155pISSN: 0513-5796, eISSN: 1976-2437          Yonsei Med J 56(4):1155-1157, 2015
Jihye Park, et al.
Yonsei Med J   http://www.eymj.org   Volume 56   Number 4   July 20151156
intubation, and the patient was extubated 3 days later and 
discharged without complications (Fig. 1C). She was diag-
nosed with endometriotic cyst and underwent laparoscopic 
right ovarian cyst enucleation.
DISCUSSION
A recent study shows that gadobutrol is highly safe, with 
0.55% of adverse drug reaction and less than 0.01% of seri-
ous adverse drug reaction requiring admission such as ana-
phylaxis.4 Besides minor adverse effects such as feeling of 
warmth and taste alteration, MRI contrasts could rarely in-
duce nephrogenic systemic fibrosis.5 However, we could not 
find direct association between MRI contrasts and the lung 
adverse reactions, and this case has a meaningful value as 
the first reported case of ARDS after the use of gadobutrol. 
Drug-induced ARDS is a progressive clinical condition 
when a drug causes alveolar degradation and flooding with 
protein-rich material and cellular debris with subsequent in-
creases in pulmonary vascular resistance. A complex array 
of endothelial injury, epithelial injury, neutrophil-mediated 
damage, cytokine-mediated inflammation and injury, oxi-
dant-mediated injury, ventilator-induced lung injury, and 
dysregulation of coagulation and fibrinolytic pathways are 
all implicated in the development.6
Risk of adverse reactions by MR contrast media have 
been reported to be lower than those of CT contrast media, 
and cross-reactivity between MR and CT contrast media has 
not yet been reported. Therefore, MR contrast study has 
been recognized as the safe alternative for iodide contrast 
media allergy patients.7 However, our patient did not show 
adverse reaction to CT contrast agent, suggesting the possi-
bility of using CT contrast media as a safe alternative for MR 
contrast allergy patients.
CASE REPORT
A 26 years old female without allergic diseases or history of 
taking medical image studies by using contrast media visit-
ed the emergency room for abdominal pain. Her abdomino-
pelvic CT with contrast media showed a right ovarian cyst 
and possible infective colitis. Her chest X-ray and blood tests 
on the day of admission did not show anything significant. 
To evaluate the ovarian cyst, she underwent pelvis MRI af-
ter injection of 7.5 mL (0.1 mL/kg body weight) of gadobu-
trol (Gadovist, Bayer Inc., Toronto, Canada) 83 hours after 
the CT examination. Fifty minutes after the injection of gado-
butrol, she presented respiratory difficulty, edema of the lips, 
nausea, vomiting, and wheezing upon auscultation. Her blood 
pressure (124/75 mm Hg) and body temperature (37.2ºC) 
were normal, but she had tachycardia (pulse rate 109/min-
ute) and tachypnea (respiratory rate 32/minute). Under the 
impression of anaphylaxis, she was given 0.5 mg of epi-
nephrine 1:1000 intramuscularly and 5 mg of dexametha-
sone twice intravenously. While applying 15 L/min of oxy-
gen via mask, arterial blood gas analysis showed pO2 of 
50.8 mm Hg and PaO2/FiO2 ratio of 63.5, and the chest X-ray 
showed bilateral central bat-wing consolidation (Fig. 1A). 
She rapidly developed acute respiratory failure that required 
mechanical ventilation (Fig. 1B). Three hours after the injec-
tion, she had hypotension (blood pressure 59/39 mm Hg) 
and tachycardia (pulse rate 112/min). Blood pressure did not 
recover after administration of 2 L of crystalloid and norepi-
nephrine (10 mcg per minute). Six hours after the infusion, 
ARDS was improved on the X-ray, and transthoracic echo-
cardiogram showed good left ventricular contractility with 
left ventricular ejection fraction of 60%. The ratio of mitral 
peak velocity of early filling to early diastolic mitral annular 
velocity was 9. Norepinephrine was stopped 16 hours after 
Fig. 1. Chest X-ray features of the patient: (A) when the symptoms presented, (B) immediately after intubation, (C) before discharge from the intensive care unit.
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consider the possibility of using CT contrast media as a safe 
alternative.
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We diagnosed our patient with ARDS. She showed some 
clinical symptoms of anaphylaxis such as dyspnea and 
wheezing, but these can be explained by ARDS. Her clinical 
manifestations were not compatible to anaphylaxis; she de-
veloped the symptoms 50 minutes after the injection of gado-
butrol, and the blood pressure was normal at the early phase 
of the event and then dropped 3 hours after the administra-
tion. Most cases of anaphylaxis after the use of contrast me-
dia occur within 15 minutes, and a study on gadobustrol 
states that 82.4% of the side effects occur within 5 minutes 
after the injection and 95.7% in 10 minutes.8 The hypoten-
sion episode was not corrected despite epinephrine and mas-
sive administration of crystalloid fluid. The clinical feature 
of this patient was quite similar to the previously reported 
anaphylactoid pulmonary edema induced by ionic iodide 
contrast media.2,3 Intradermal skin test and the measurement 
of serum tryptase at the time of the episode might have 
helped the differentiation of the diagnosis, but they were not 
done. Some investigators suggest the usefulness of 1:10 di-
luted intradermal skin test for IgE mediated gadolinium con-
trast media allergy,9 but IgE mediated mechanism may not 
be critical for the development of ARDS. Furthermore, posi-
tive and negative predictive values of skin test for the diag-
nosis of IgE mediated gadolinium allergic diseases are yet 
unknown.
Besides gadobutrol, the MRI contrast media which our 
patient used, there are other gadolinium-based contrast me-
dia such as gadoteric acid, gadobenate, and gadodiamide. 
Controversy exists whether the allergic reactions of gado-
linium contrast media are structure dependent. Several in-
vestigators have reported higher rate of allergic reaction by 
gadomenate dimeglumine than other MR contrast media,10 
suggesting the presence of specificities of gadolinium con-
trast media for provoking adverse reactions.
Recently, increased need for health check-ups led to in-
creased use of MRI with contrast media as well. Doctors 
and other practitioners should always keep in mind the risk 
of ARDS after the use of gadolinium contrast media and 
